119 related articles for article (PubMed ID: 8016979)
21. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
22. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
23. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
Jayadev A; Stiglitz J
Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
[TBL] [Abstract][Full Text] [Related]
24. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
25. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
26. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
27. The quiet rise of the clinical contractor.
Wadman M
Nature; 2006 May; 441(7089):22-3. PubMed ID: 16672945
[No Abstract] [Full Text] [Related]
28. [Is society going to finance projects of drug companies?].
Bake B
Lakartidningen; 1999 May; 96(19):2327-8. PubMed ID: 10377674
[No Abstract] [Full Text] [Related]
29. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
30. Patients, physicians, and clinical trials: the other side of the coins.
Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
[No Abstract] [Full Text] [Related]
31. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living?
Elliott C
New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451
[No Abstract] [Full Text] [Related]
32. Industry money skews drug overviews.
Giles J
Nature; 2005 Sep; 437(7058):458-9. PubMed ID: 16177748
[No Abstract] [Full Text] [Related]
33. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M; Nagata T
Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
[TBL] [Abstract][Full Text] [Related]
34. [Dishonesty in clinical trials is expensive for the society 3].
Waldorff S
Ugeskr Laeger; 2003 Jun; 165(26):2672-3; author reply 2673-4. PubMed ID: 12886557
[No Abstract] [Full Text] [Related]
35. [Dishonesty in clinical trials is expensive for the society 2].
Lund BA; Nordby G
Ugeskr Laeger; 2003 Jun; 165(26):2672. PubMed ID: 12886556
[No Abstract] [Full Text] [Related]
36. [Dishonesty in clinical trials is expensive for the society 1].
Heslet L; Nielsen JD; Schierbeck J
Ugeskr Laeger; 2003 Jun; 165(26):2671-2. PubMed ID: 12886555
[No Abstract] [Full Text] [Related]
37. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
38. Biotech and pharma face more costly clinical trials.
Brower V
Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
[No Abstract] [Full Text] [Related]
39. The Gordian knot of developing tocolytics.
Goodwin TM
J Soc Gynecol Investig; 2004 Sep; 11(6):339-41. PubMed ID: 15350245
[No Abstract] [Full Text] [Related]
40. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
